Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome / 대한내과학회지
Korean Journal of Medicine
;
: 496-500, 2014.
Artículo
en Coreano
| WPRIM
| ID: wpr-176486
ABSTRACT
In randomized phase 3 clinical trials azacitidine has been shown to prolong survival in patients with higher-risk myelodysplastic syndrome (MDS). Therefore, azacitidine therapy should be considered for treating MDS patients with higher-risk disease. A 78-year-old male was administered the first cycle of azacitidine treatment for higher-risk MDS. On day three of chemotherapy he complained of fever and dyspnea, and radiographic findings revealed bilateral perihilar-peribronchial infiltration and a small amount of pleural effusion. Considering the possibility of pneumonia, intravenous broad-spectrum antibiotics were administered and azacitidine therapy was discontinued. Upon improvement of the patient's subjective symptoms and radiographic abnormalities, azacitidine therapy was resumed. However, fever and dyspnea developed again upon recommencement of azacitidine therapy. A diagnosis was made of azacitidine-induced lung injury and corticosteroid treatment was administered. Although lung injury is a rare complication induced by azacitidine, physicians should be aware of this life-threatening side effect.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Derrame Pleural
/
Neumonía
/
Azacitidina
/
Síndromes Mielodisplásicos
/
Diagnóstico
/
Quimioterapia
/
Disnea
/
Lesión Pulmonar
/
Fiebre
/
Antibacterianos
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio diagnóstico
Límite:
Anciano
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS